Lincoln Pharma soon to launch diclofenac rectal spray in Indian market
Lincoln Pharmaceuticals Ltd has received Drug Controller General of India (DCGI)’s approval for liquid diclofenac metered-dose rectal spray and will soon launch in the Indian market.
Recently, company was awarded with a patent for its liquid diclofenac rectal spray. The company is also planning to apply for a global patent for this novel solution.
Lincoln Pharma’s liquid rectal spray dosage offers faster and better absorption of the drug resulting in quick relief and speedy recovery to patients compared to the existing therapeutic options.
Clinical trials conducted suggest that diclofenac rectal spray is highly effective in patients suffering from pre and post operative pain, gynaecological surgery and musculoskeletal disorders such as muscular pain, pain associated with arthritis, acute pain in renal colic and mild body ache.
Also read: Wockhardt gets DCGI nod for 2 new antibiotics
The company is also considering a proposal to set up a US Food and Drug Administration (FDA) facility in Gujarat to expand global footprint and tap the export opportunities.
The company is building a strong portfolio in lifestyle and chronic segment especially women healthcare and dermatology to complement its strong presence in acute segment.
The company works with a vision for nurturing innovations and bringing them to Indian patients at an affordable cost to create “Healthcare for All”.
“On the back of higher research and development, the company plans to launch many NDDS based products in India.
We have developed many new drug delivery dosage forms over years and has a track record of launching many first-of-its-kind innovative products,” said Mahendra Patel, MD, Lincoln Pharmaceuticals Ltd.
